Literature DB >> 15289459

Reprogramming of a melanoma genome by nuclear transplantation.

Konrad Hochedlinger1, Robert Blelloch, Cameron Brennan, Yasuhiro Yamada, Minjung Kim, Lynda Chin, Rudolf Jaenisch.   

Abstract

We have used nuclear transplantation to test whether the reprogramming activity of oocytes can reestablish developmental pluripotency of malignant cancer cells. We show here that the nuclei of leukemia, lymphoma, and breast cancer cells could support normal preimplantation development to the blastocyst stage but failed to produce embryonic stem (ES) cells. However, a blastocyst cloned from a RAS-inducible melanoma nucleus gave rise to ES cells with the potential to differentiate into multiple cell types in vivo including melanocytes, lymphocytes, and fibroblasts. Chimeras produced from these ES cells developed cancer with higher penetrance, shorter latency, and an expanded tumor spectrum when compared with the donor mouse model. These results demonstrate that the secondary changes of a melanoma nucleus are compatible with a broad developmental potential but predispose mice to melanomas and other malignant tumors on reactivation of RAS. Our findings serve as a paradigm for studying the tumorigenic effect of a given cancer genome in the context of a whole animal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289459      PMCID: PMC517407          DOI: 10.1101/gad.1213504

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  52 in total

1.  A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells.

Authors:  Hidesato Ogawa; Kei-Ichiro Ishiguro; Stefan Gaubatz; David M Livingston; Yoshihiro Nakatani
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

Review 2.  Nuclear transplantation: lessons from frogs and mice.

Authors:  Konrad Hochedlinger; Rudolf Jaenisch
Journal:  Curr Opin Cell Biol       Date:  2002-12       Impact factor: 8.382

Review 3.  Rules for making human tumor cells.

Authors:  William C Hahn; Robert A Weinberg
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 4.  Chromatin modification and epigenetic reprogramming in mammalian development.

Authors:  En Li
Journal:  Nat Rev Genet       Date:  2002-09       Impact factor: 53.242

5.  Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.

Authors:  William M Rideout; Konrad Hochedlinger; Michael Kyba; George Q Daley; Rudolf Jaenisch
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

Review 6.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

7.  Monoclonal mice generated by nuclear transfer from mature B and T donor cells.

Authors:  Konrad Hochedlinger; Rudolf Jaenisch
Journal:  Nature       Date:  2002-02-10       Impact factor: 49.962

8.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

9.  Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

Authors:  Richard Sharp; Juan A Recio; Chamelli Jhappan; Toshiyuki Otsuka; Shiquan Liu; Yanlin Yu; Wenjing Liu; Miriam Anver; Fariba Navid; Lee J Helman; Ronald A DePinho; Glenn Merlino
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

10.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  129 in total

1.  Biography of Rudolf Jaenisch.

Authors:  Christen Brownlee
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

Review 2.  Epigenetic memories: structural marks or active circuits?

Authors:  Floriane Nicol-Benoît; Pascale Le-Goff; Yves Le-Dréan; Florence Demay; Farzad Pakdel; Gilles Flouriot; Denis Michel
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

Review 3.  Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications.

Authors:  Said Assou; Imène Boumela; Delphine Haouzi; Tal Anahory; Hervé Dechaud; John De Vos; Samir Hamamah
Journal:  Hum Reprod Update       Date:  2010-08-17       Impact factor: 15.610

Review 4.  Redefining regulation of DNA methylation by RNA interference.

Authors:  Viswanathan Muthusamy; Marcus Bosenberg; Narendra Wajapeyee
Journal:  Genomics       Date:  2010-07-08       Impact factor: 5.736

5.  Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention.

Authors:  Jared M Fischer; Arnout G Schepers; Hans Clevers; Darryl Shibata; R Michael Liskay
Journal:  Carcinogenesis       Date:  2013-08-29       Impact factor: 4.944

6.  Tumour development due to stroma permissiveness.

Authors:  Edna Cukierman
Journal:  J Biosci       Date:  2005-12       Impact factor: 1.826

Review 7.  Epigenetic inheritance during the cell cycle.

Authors:  Aline V Probst; Elaine Dunleavy; Geneviève Almouzni
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

Review 8.  Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.

Authors:  Ion G Motofei
Journal:  Curr Treat Options Oncol       Date:  2019-05-06

Review 9.  Urothelial carcinoma: stem cells on the edge.

Authors:  William D Brandt; William Matsui; Jonathan E Rosenberg; Xiaobing He; Shizhang Ling; Edward M Schaeffer; David M Berman
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 10.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.